SCHEMBL388032

SCHEMBL388032

O=S(=O)(Cl)c1cc(Cl)sc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
CDK1 P06493 3/20 0.47
CCNB1 P14635 3/20 0.47
CCNA2 P20248 3/20 0.47
CCND1 P24385 3/20 0.47
CDK2 P24941 3/20 0.47
CDK7 P50613 3/20 0.47
CCNH P51946 3/20 0.47
CCNA1 P78396 3/20 0.47
CDK6 Q00534 3/20 0.47
TDP1 Q9NUW8 1/20 0.44
S100A9 P06702 4/20 0.42
DAO P14920 1/20 0.40
PFKFB3 Q16875 1/20 0.40
APP P05067 1/20 0.40
ACLY P53396 1/20 0.37
GSK3B P49841 1/20 0.36
EPHX2 P34913 1/20 0.35
TYMS P04818 1/20 0.35
TRPV4 Q9HBA0 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888545 0.82 PKM (0.44) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL1645094 0.79 PKM (0.52) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL12560498 0.79 PKM (0.52) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL2265194 0.79 PKM (0.35) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL6038652 0.79 PKM (0.52) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL4616033 0.79 PKM (0.52) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL301846 0.79 PKM (0.52) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL10590843 0.77 CDK1 (0.41) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL5137127 0.77 PKM (0.50) PKMCDK1CCNB1CCNA2CCND1
SCHEMBL11757841 0.77 PKM (0.50) PKMCDK1CCNB1CCNA2CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
WO-2026102632-A1 BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION HANSONSBECK INDUSTRIES LIMITED (CN) 2026-05-21 WO disclosed
EP-4146651-B1 SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS NINGXIA ACADEMY AGRICULTURE & FORESTRY SCIENCES (CN) 2026-03-04 EP disclosed
US-12410166-B2 Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) 2025-09-09 US disclosed
WO-2025075722-A1 PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS FORMOSA PLASTICS CORPORATION, U.S.A. (US) 2025-04-10 WO disclosed
US-20250115687-A1 PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS FORMOSA PLASTICS CORP USA (US) 2025-04-10 US disclosed
US-20250101143-A1 CATALYST FOR OLEFIN POLYMERIZATION AND PRODUCTION METHOD FOR OLEFIN-BASED POLYMER THE UNIVERSITY OF TOKYO (JP) 2025-03-27 US disclosed
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use Oxford Drug Design Limited (GB) 2025-03-11 US disclosed
CN-114846000-B 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2025-01-03 CN disclosed
EP-4442714-A1 CATALYST FOR OLEFIN POLYMERIZATION AND PRODUCTION METHOD FOR OLEFIN-BASED POLYMER The University of Tokyo (JP) 2024-10-09 EP disclosed
US-5272128-A Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1993-12-21 US disclosed
EP-0511826-A2 Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1992-11-04 EP disclosed
US-4997847-A Thromboxane A2 antagonists SMITH KLINE & FRENCH LABORATORIES LIMITED (DE) 1991-03-05 US disclosed
EP-0304271-A2 Omega-arylsulphonamidoalkanoic acids for treatment of thromboxane medited diseases SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-02-22 EP disclosed
EP-0001113-B1 THIENOTHIAZINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-11-11 EP disclosed
US-4180662-A ANTIINFLAMMATORY, ANALGESIC, ANTIRHEUMATIC, ANTITHROMBOTIC HOFFMANN-LA ROCHE INC. (US) 1979-12-25 US disclosed
EP-0001113-A1 Thienothiazine derivatives, their preparation and compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-03-21 EP disclosed
US-4075347-A THIOPHENES CHEVRON RESEARCH COMPANY (US) 1978-02-21 US disclosed
US-3998961-A Fungicidal sulfonamidothiophenes CHEVRON RESEARCH COMPANY (US) 1976-12-21 US disclosed
US-3996243-A Fungicidal 5-dialkylamino-4-nitrosulfonamidothiophenes CHEVRON RESEARCH COMPANY (US) 1976-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use AARS1, ASNS, GARS1 PKM 4165/4885CDK1 1524/4885CCNB1 2363/4885
US-12410166-B2 Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors MGAM, MGAM2, ABCC1 PKM 1397/4885CDK1 4513/4885CCNB1 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.